Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (141-150 of 437) with videos related to

Pageof 44
Sort By:
Journal for Immunotherapy of Cancer|February 16, 2021
Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancerSebastian Marwitz, Carmen Ballesteros-Merino, Shawn M Jensen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2018
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057Martin Reck, Julie Brahmer, Bryan Bennett, et al.
Lung Cancer (Amsterdam, Netherlands)|May 23, 2006
Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trialMartin Reck, Joachim von Pawel, Hans-Nicholas Macha, et al.
Oncology Research and Treatment|September 12, 2016
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, et al.
Lung Cancer (Auckland, N.Z.)|November 22, 2017
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancerWolfgang Schuette, Claus-Peter Schneider, Walburga Engel-Riedel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2013
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancerMartin Reck, Maciej Krzakowski, Ewa Chmielowska, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2020
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapyMartin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
Journal of Oncology|September 20, 2019
High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening BiomarkersAlessandra Rossi, Minna Voigtlaender, Hans Klose, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2009
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerMark J McKeage, Martin Reck, Michael B Jameson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2022
MET alterations in NSCLC-Current Perspectives and Future ChallengesJordi Remon, Lizza E L Hendriks, Giannis Mountzios, et al.
Pageof 44

Showing results (141-150 of 437) with videos related to

Sort By:
Pageof 44
Journal for Immunotherapy of Cancer|February 16, 2021
Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancerSebastian Marwitz, Carmen Ballesteros-Merino, Shawn M Jensen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2018
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057Martin Reck, Julie Brahmer, Bryan Bennett, et al.
Lung Cancer (Amsterdam, Netherlands)|May 23, 2006
Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trialMartin Reck, Joachim von Pawel, Hans-Nicholas Macha, et al.
Oncology Research and Treatment|September 12, 2016
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, et al.
Lung Cancer (Auckland, N.Z.)|November 22, 2017
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancerWolfgang Schuette, Claus-Peter Schneider, Walburga Engel-Riedel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2013
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancerMartin Reck, Maciej Krzakowski, Ewa Chmielowska, et al.
Lung Cancer (Amsterdam, Netherlands)|September 14, 2020
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapyMartin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
Journal of Oncology|September 20, 2019
High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening BiomarkersAlessandra Rossi, Minna Voigtlaender, Hans Klose, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2009
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerMark J McKeage, Martin Reck, Michael B Jameson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2022
MET alterations in NSCLC-Current Perspectives and Future ChallengesJordi Remon, Lizza E L Hendriks, Giannis Mountzios, et al.
Pageof 44